Synonyms: example 1 [WO2016193844A1]
Compound class:
Synthetic organic
Comment: This vanin 1 inhibitor was claimed (as Example 1) in Pfizer's patent WO2016193844A1 [2], and the structure was disclosed in a peer reviewed publication in 2021 [3]. Blocking the pantetheinase activity of vanin 1 did not provide the hypothesised protective effect in models of acute and chronic kidney disease.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Casimiro-Garcia A, Condon JS, Flick AC, Gopalsamy A, Kirincich SJ, Mathias JP, Strobach JW, Xiang JS, Xing LH, Wang X. (2018)
Novel heterocyclic compounds as inhibitors of vanin-1 enzyme. Patent number: US20180148420A1. Assignee: Pfizer Inc. Priority date: 29/05/2015. Publication date: 31/05/2018. |
2. Casimiro-Garcia A, Condon JS, Flick AC, Gopalsamy A, Kirincich SJ, Mathias JP, Strohbach JW, Xiang JS, Xing LH, Wang X. (2016)
Novel heterocyclic compounds as inhibitors of vanin-1 enzyme. Patent number: WO2016193844A1. Assignee: Pfizer. Priority date: 29/05/2015. Publication date: 08/12/2016. |
3. Unterschemmann K, Ehrmann A, Herzig I, Andreevski AL, Lustig K, Schmeck C, Eitner F, Grundmann M. (2021)
Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease. Am J Physiol Renal Physiol, 320 (1): F61-F73. [PMID:33196323] |